TheraGenetics raises $6M for personalized medicine
TheraGenetics, a London biotechnology company developing personalized-medicine diagnostics, raised $6 million (£3 million) in a first funding round. The company is working on a diagnostic test designed to predict which patients are most likely to respond to antipsychotic drugs, including those for schizophrenia.
Swarraton Partners led the round, joined by Tudor Capital, IP Venture Fund, and IP Group. TheraGenetics was spun out of the King’s College Institute of Psychiatry.
Next Story: Cellumen takes in $8.7M for drug-discovery aids
Previous Story: FDA clears new uses for Aragon Surgical's laparascopic device
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.
VB Writers
Ben PopperEast Coast Editor
Dean TakahashiLead Writer, GamesBeat
Devindra HardawarNational Editor, MobileBeat Lead
Dylan TweneyExecutive Editor
ShoeEditor-in-Chief, GamesBeat
Heather KellySenior Editor
Jennifer Van GroveWriter
Jolie O'DellWriter
Matt MarshallFounder & Editor-in-Chief
Meghan KellyWriter
Sarah MitroffEditorial Assistant
Sean LudwigWriter
Sebastian HaleyReviews Editor, GamesBeat
Tom CheredarWriter
Ciara ByrneContributor
Julia PlevinContributor
Lindsey ComptonContributor
